EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

α-Lipoic Acid, with or Without Ambrisentan, Attenuates Experimental Pulmonary Arterial Hypertension: Associations with AMPK/mTOR/NF-κB Signaling and Kallistatin

Seyhan Ayik iD, Mustafa Huz iD, Zeynep Ulutas iD, Mehmet Ertugrul Balkar iD, Kevser Tanbek iD, Rumeysa Sonmez iD, Ruveyda Ummugulsum Unal, Eylem Karadag iD, Seymanur Baydak, Lokman Hekim Tanriverdi iD, Onural Ozhan iD

Biomolecules · 2026

DOI: 10.3390/biom16101432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Seyhan Ayik und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Faculty of Medicine, İnönü University, Malatya 44280, Türkiye. Hauptthemen laut MEDLINE: Pyridazines, Thioctic Acid, Pulmonary Arterial Hypertension, Serpins. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inonu University, İnönü University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular remodeling driven by excessive cellular proliferation and inflammation. Targeting both vasoconstriction and vascular remodeling represents a key therapeutic strategy. Alpha-lipoic acid (α-LA), a metabolic and anti-inflammatory modulator, is associated with modulation of AMPK/mTOR/NF-κB signaling, whereas ambrisentan (AMB) is an endothelin receptor antagonist with established vasodilatory effects. We investigated the beneficial effects of α-LA and AMB, administered alone or in combination, in a monocrotaline (MCT)-induced PAH rat model.

Methods

Male rats were randomly assigned to control, MCT, α-LA, AMB, and α-LA + AMB groups. PAH was induced by a single subcutaneous injection of monocrotaline (60 mg/kg). Treatments were administered between days 22 and 35. Echocardiographic measurements were obtained, and histopathological, immunohistochemical, and biochemical analyses were performed in lung and cardiac tissues and in serum. Sample sizes analyzed per outcome were: echocardiography (Control: n = 10, MCT: n = 10, α-LA: n = 8, AMB: n = 9, α-LA + AMB: n = 10), histology (n = 10/group), RVSP (Control: n = 7, MCT: n = 8, α-LA: n = 8, AMB: n = 7, α-LA + AMB: n = 9), Fulton index (Control: n = 10, MCT: n = 10, α-LA: n = 12, AMB: n = 9, α-LA + AMB: n = 10), and ELISA (n = 8/group). Statistical analyses were performed using a web-based statistical software, applying one-way ANOVA or the Kruskal–Wallis test according to data distribution. Results were considered statistically significant at p < 0.05.

Results

MCT administration caused pulmonary hypertension and right ventricular remodeling, evidenced by increased RVSP, Fulton index, medial wall thickness, cardiomyocyte diameter, PCNA, α-SMA, p-mTOR, and NF-κB, together with reduced PAT, TAPSE, kallistatin, and p-AMPK levels. α-LA and AMB monotherapy improved right ventricular function and inflammation. Combination therapy produced hemodynamic and structural improvements relative to MCT that were generally comparable to, rather than significantly greater than, either monotherapy, and showed attenuated antiproliferative effects, with higher cardiomyocyte diameter and PCNA levels than either monotherapy alone. All treatments suppressed mTOR activation and the NF-κB increase, accompanied by increased serum kallistatin levels, whereas a significant increase in p-AMPK relative to MCT was observed only with AMB monotherapy.

Conclusions

These findings demonstrate that α-LA exerts antiproliferative, anti-remodeling, and anti-inflammatory effects in experimental PAH, suggesting that the AMPK/mTOR/NF-κB signaling pathway and kallistatin may be potential therapeutic targets in pulmonary vascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridazinesThioctic AcidPulmonary Arterial HypertensionSerpinsAnimalsNF-kappa BMaleTOR Serine-Threonine KinasesRatsSignal TransductionAMP-Activated Protein KinasesMonocrotalineDisease Models, AnimalRats, Sprague-DawleyPhenylpropionates

Stichwörter der Autor:innen

AMPKAlpha-lipoic acidambrisentankallistatinmTORpulmonary arterial hypertension

Substanzen

NF-kappa BTOR Serine-Threonine KinasesambrisentanAMP-Activated Protein KinasesPyridazinesThioctic AcidMonocrotalineSerpinsmTOR protein, ratPhenylpropionates

Autor:innen und Institutionen

  • Department of Medical Pharmacology, Faculty of Medicine, İnönü University, Malatya 44280, Türkiye.
  • Department of Medical Pathology, Faculty of Medicine, İnönü University, Malatya 44280, Türkiye.
  • Department of Cardiology, Faculty of Medicine, İnönü University, Malatya 44280, Türkiye.
  • Department of Physiology, Faculty of Medicine, İnönü University, Malatya 44280, Türkiye.
  • Department of Medical Pharmacology, Institute of Health Sciences, İnönü University, Malatya 44280, Türkiye.

ORCID-Profile: Seyhan Ayik, Mustafa Huz, Zeynep Ulutas, Mehmet Ertugrul Balkar, Kevser Tanbek, Rumeysa Sonmez, Eylem Karadag, Lokman Hekim Tanriverdi, Onural Ozhan

Förderung

  • Inonu University
  • İnönü University

Zitieren

APA

Ayik, S., Huz, M., Ulutas, Z., Balkar, M. E., Tanbek, K., Sonmez, R., Unal, R. U., Karadag, E., Baydak, S., Tanriverdi, L. H., & Ozhan, O. (2026). α-Lipoic Acid, with or Without Ambrisentan, Attenuates Experimental Pulmonary Arterial Hypertension: Associations with AMPK/mTOR/NF-κB Signaling and Kallistatin. Biomolecules. https://doi.org/10.3390/biom16101432

Vancouver

Ayik S, Huz M, Ulutas Z, Balkar ME, Tanbek K, Sonmez R, et al. α-Lipoic Acid, with or Without Ambrisentan, Attenuates Experimental Pulmonary Arterial Hypertension: Associations with AMPK/mTOR/NF-κB Signaling and Kallistatin. Biomolecules. 2026. doi:10.3390/biom16101432

BibTeX
@article{Ayik2026,
  author = {Ayik, Seyhan and Huz, Mustafa and Ulutas, Zeynep and Balkar, Mehmet Ertugrul and Tanbek, Kevser and Sonmez, Rumeysa and Unal, Ruveyda Ummugulsum and Karadag, Eylem and Baydak, Seymanur and Tanriverdi, Lokman Hekim and Ozhan, Onural},
  title = {α-Lipoic Acid, with or Without Ambrisentan, Attenuates Experimental Pulmonary Arterial Hypertension: Associations with AMPK/mTOR/NF-κB Signaling and Kallistatin},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16101432}
}
Kostenlos starten →